4,4'-Sulfonyldiphenol

Synonyms: 双酚 S; Bisphenol S; Bis(4-hydroxyphenyl) sulfone
4,4'-Sulfonyldiphenol (Bisphenol S; Bis(4-hydroxyphenyl) sulfone) 是一种 Bisphenol A (MS-T06982) 的替代品,常被广泛应用于工业和消费品中,它是一种口服有效的雌激素受体 (ER) 激动剂,能够竞争性结合甲状腺激素受体 (TR),对 TRα 和 TRβ 的 IC50 值分别为 2650 μM 和 2294 μM,从而影响乳腺发育并降低小鼠胎儿睾丸中雄激素受体 (AR) 的表达;此外,它通过上调 EZH2 介导的 PI3K/AKT/mTOR 通路促进胶质母细胞瘤的进展,在慢性暴露下可通过上调 JunB 和 Atf3 导致小鼠肝脏显著脂质沉积和血脂异常,低剂量时具有致肥胖作用,通过改变肠道微生物组诱发肠道炎症,并加速斑马鱼胚胎幼虫动脉粥样硬化的进展。
产品编号: MS-C36381 纯度: 99.44% CAS No.: 80-09-1 分子式: C12H10O4S 分子量: 250.28
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
25g
询价
3-5 天
50g
询价
3-5 天
100g
询价
3-5 天
500g
询价
3-5 天
1kg
询价
3-5 天

产品描述

4,4'-Sulfonyldiphenol (Bisphenol S; Bis(4-hydroxyphenyl) sulfone) 是一种 Bisphenol A (MS-T06982) 的替代品,常被广泛应用于工业和消费品中,它是一种口服有效的雌激素受体 (ER) 激动剂,能够竞争性结合甲状腺激素受体 (TR),对 TRα 和 TRβ 的 IC50 值分别为 2650 μM 和 2294 μM,从而影响乳腺发育并降低小鼠胎儿睾丸中雄激素受体 (AR) 的表达;此外,它通过上调 EZH2 介导的 PI3K/AKT/mTOR 通路促进胶质母细胞瘤的进展,在慢性暴露下可通过上调 JunB 和 Atf3 导致小鼠肝脏显著脂质沉积和血脂异常,低剂量时具有致肥胖作用,通过改变肠道微生物组诱发肠道炎症,并加速斑马鱼胚胎幼虫动脉粥样硬化的进展。

生物实验数据

生物活性 4,4'-Sulfonyldiphenol (Bisphenol S; Bis(4-hydroxyphenyl) sulfone) is a substitute for Bisphenol A (MS-T06982) and is widely used in industrial and consumer products; it is an orally active estrogen receptor (ER) agonist that competitively binds thyroid hormone receptor (TR) with IC50 values of 2650 μM for TRα and 2294 μM for TRβ, thereby affecting mammary gland development and reducing androgen receptor (AR) expression in mouse fetal testes; furthermore, it promotes glioblastoma progression by upregulating the EZH2-mediated PI3K/AKT/mTOR pathway, and under chronic exposure it causes significant hepatic lipid deposition and dyslipidemia in mice by upregulating JunB and Atf3, exerts obesogenic effects at low doses, induces intestinal inflammation by altering the gut microbiome, and accelerates atherosclerosis progression in zebrafish embryos/larvae.
体外研究
(In Vitro)

4,4’-Sulfonyldiphenol (0-50 μM) 可诱导甲状腺激素 (TH) 依赖性 GH3 细胞增殖,并在存在 T3 的情况下抑制 T3 (MS-Q25762) 诱导。
4,4’-Sulfonyldiphenol (100 μM,24 小时) 通过 JunB/ATF3 轴显著增加 AML12 和原代肝细胞中的脂质沉积。
4,4’-Sulfonyldiphenol (0.001-100 μM,4-24 小时) 在 0.1 µM 浓度下促进 U-87 MG 细胞的增殖和迁移,并且似乎与 EZH2 介导的 PI3K/AKT/mTOR 的激活有关途径。
4,4’-Sulfonyldiphenol (0.01-1 μM,0-24 小时) 可增强巨噬细胞中氧化低密度脂蛋白 (oxLDL) 的泡沫细胞形成。

Cell Proliferation Assay

Cell Line: U-87 MG cells
Concentration: 0, 0.001, 0.01, 0.1, 1, 10 and 100 μM
Incubation Time: 4 and 8 h
Result: Significantly increased the proliferation rate at 0.1 μM, and the effect was more significant after 8 hours of treatment than after 4 hours.

Cell Migration Assay

Cell Line: U-87 MG cells
Concentration: 0.1 μM
Incubation Time: 0, 2, 4, 6, 8, 10 and 12 h
Result: Significantly increased the mobility within 12 hours.

Cell Invasion Assay

Cell Line: U-87 MG cells
Concentration: 0.1, 1 and 10 μM
Incubation Time: 24 h
Result: Induced glioblastoma invasion in U-87 MG cells.

RT-PCR

Cell Line: U-87 MG cells
Concentration: 0.1 μM
Incubation Time: 4 and 8 h
Result: Increased the mRNA level of EZH2.

Western Blot Analysis

Cell Line: U-87 MG cells
Concentration: 0.1 μM
Incubation Time: 4 and 8 h
Result: Increased the expression of EZH2, p-PI3K, p-AKT, p-mTOR and p-4E-BP1.
Decreased the expression of PIK3IP1.
体内研究
(In Vivo)

4,4’-Sulfonyldiphenol (2-2000 μg/kg,口服,从妊娠第 9 天开始直至哺乳期第 2 天或第 20 天) 会改变乳腺上皮的生长,并使雄性小鼠对青春期遇到的额外雌激素暴露更加敏感。
4,4’-Sulfonyldiphenol (0.2-50 μg/kg,口服,从妊娠第 0 天开始每日一次,持续至子代 23 周龄) 在低剂量以及围产期和慢性暴露后,可导致雄性小鼠肥胖。
4,4’-Sulfonyldiphenol (0-10 μM,单剂量) 可诱导黑斑侧褶蝌蚪的 TH 反应基因转录,但在T3 以双相浓度反应方式改变 T3 诱导的基因转录。
4,4’-Sulfonyldiphenol (0.1-1 mg/kg,灌胃,每日一次,持续 3 个月) 诱导小鼠肝脏出现显著脂质沉积和血脂异常,并易患代谢功能障碍相关脂肪变性肝病 (MASLD)。
4,4’-Sulfonyldiphenol (0.1-1 mg/kg,灌胃,每日一次,持续 3 个月) 通过改变小鼠肠道微生物群诱发肠道炎症。
4,4’-Sulfonyldiphenol (0-100 μg/L,持续 15-45 天) 在斑马鱼胚胎幼虫模型中加速了动脉粥样硬化性心血管疾病的进展 (ASCVD)。

Animal Model: Long-term and short-term exposure effect assessment established in female CD-1 mice
Dosage: 2 and 200 μg/kg (long-term); 2, 200, and 2000 μg/kg (short-term)
Administration: Oral administration (p.o.), once daily starting on pregnancy day 9 through lactation day 20 (long-term) and starting on pregnancy day 9 through lactation day 2 (short-term)
Result: Showed signs of ductal formation in the mammary gland and significantly enlarged the intercellular spaces between the tissues.
Increased ERα expression in epithelial cells and dose-dependently decreased AR expression in the stroma.
Increased the right duct area in all groups, and the left duct area also increased significantly in the high-dose group.
Altered the response of male mice to a pre-pubertal estrogen challenge.
Animal Model: High fat diet model established in pregnant C57Bl/6J mice
Dosage: 0.2, 1.5, 50 µg/kg
Administration: Oral administration (p.o.) with water, once daily beginning at gestational day 0 and continuing in offspring up to 23-weeks old
Result: Significantly increased in body weight and fat mass on a high-fat diet.
Had no effect on the food intake and energy expenditure.
Exhibited a weak but significant hypercholesterolemia with a fold increase of 1.21 and 1.29 at 1.5 and 50 µg/kg, respectively.
Showed a significant decrease of the AUC (increase of blood TG clearance).
Significantly increased the calculated HOMA-IR index in mice exposed to 1.5 and 50 µg/kg.
Induced a significant overexpression of SOCS3 mRNA and a significant mRNA down-regulation of INSR and adiponectin.
Induced a weak but significant decrease in mRNA expression of HSL and PPARγ genes in adipose tissue of male mice fed with a HFD.
Animal Model: MASLD model established in 7-week-old C57BL/6 male mice
Dosage: 0.1 and 1 mg/kg
Administration: Oral gavage (i.g.), once daily for 3 months
Result: Induced MASLD phenotype: elevated LDL, increased NEFA, and elevated ALT.
Showed obvious lipid droplet accumulation.
Animal Model: Intestinal inflammation model established in 6-7 week old male C57BL/6 mice
Dosage: 0.1 and 1 mg/kg alone and 1 mg/kg with antibiotic cocktail (ABX)
Administration: Oral gavage (i.g.), once daily for 3 months alone and also for 3 months, during the exposure process, every two-week ABX treatment was followed by a two-week recovery in cycles
Result: Led to typical features of intestinal inflammation: significant shortening of colon length, tissue pathological damage, increased immune cell infiltration and apoptosis.
Induced bacterial imbalance, increasing pro-inflammatory bacteria and decreasing anti-inflammatory bacteria.
Caused an increase in arachidonic acid (pro-inflammatory) and a decrease in madecainic acid (anti-inflammatory).
Normalized intestinal inflammation, improved metabolism after antibiotic intervention.
性状 固体
颜色 White to yellow

化学信息

分子量 250.28
分子式 C12H10O4S
CAS No. 80-09-1
别名 双酚 S; Bisphenol S; Bis(4-hydroxyphenyl) sulfone

储存&溶解度

储存方式

Store at room temperature 3 years

In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (399.55 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.9955 mL19.9776 mL39.9553 mL99.8881 mL
5 mM0.7991 mL3.9955 mL7.9911 mL19.9776 mL
10 mM0.3996 mL1.9978 mL3.9955 mL9.9888 mL
15 mM0.2664 mL1.3318 mL2.6637 mL6.6592 mL
20 mM0.1998 mL0.9989 mL1.9978 mL4.9944 mL
25 mM0.1598 mL0.7991 mL1.5982 mL3.9955 mL
30 mM0.1332 mL0.6659 mL1.3318 mL3.3296 mL
40 mM0.0999 mL0.4994 mL0.9989 mL2.4972 mL
50 mM0.0799 mL0.3996 mL0.7991 mL1.9978 mL
60 mM0.0666 mL0.3330 mL0.6659 mL1.6648 mL
80 mM0.0499 mL0.2497 mL0.4994 mL1.2486 mL
100 mM0.0400 mL0.1998 mL0.3996 mL0.9989 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用,-20°C储存时,请在6个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础